Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Antiviral Res. 2017 Dec 15;150:112–122. doi: 10.1016/j.antiviral.2017.12.008

Figure 6. Combination of IHVR-19029 and T-705 against EBOV in a mouse model.

Figure 6

(A) Survival rate of EBOV infected mice treated with doses of T-705 ranging from 0.325 mg/kg to 40 mg/kg or 0.4% carboxymethylcellulose for placebo control once daily via oral route for 10 days immediately after infection (n=10 per group). (B and C) Survival rate of EBOV infected mice treated with 0.325 mg/kg of T-705 once daily orally, 50 or 75 mg/kg of IHVR-19029 twice daily via IP injection, either alone or in combination for 10 days immediately after infection. (D and E) Survival rate of EBOV infected mice treated with 1.6 mg/kg of T-705, 50 or 75 mg/kg of IHVR-19029, either alone or in combination for 10 days immediately after infection. Animals treated with vehicles served as placebo controls (n=9 per group). P values were calculated with Log-rank (Mantel-cox) test. *P<0.05; **P<0.01; ***P<0.001; ns, no significance.